カペシタビンの2030年までの市場予測： タイプ別、適応症別、流通チャネル別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、カペシタビンの世界市場は2023年に4億3,636万米ドルを占め、予測期間中に6.9％のCAGRで成長し、2030年までに6億9,613万米ドルに達すると予想されています。

カペシタビンと呼ばれる化学療法薬は、腹部がん、大腸がん、乳がんなど様々ながんの治療に使用されます。XelodaCapecitabineの商品名で市販されており、乳がんの単剤療法や転移性治療薬として使用される一方、大腸がんの場合は、放射線療法を併用したネオアジュバント療法として使用されることが多いです。その有効性、比較的管理しやすい副作用、様々ながんと闘う人々の生存率と生活の質を改善する役割で知られています。

米国がん学会の報告によると、2017年には米国で結腸・直腸がんによる新規患者が約135,430人、死亡者が50,260人と推定されています。

がん患者の増加

化学療法薬であるカペシタビンは、乳がん、大腸がん、胃がんなど複数のがん種の治療に広く使用されています。カペシタビンの経口投与は、体内で活性型に変換される能力と相まって、がん治療に便利で強力な選択肢となっています。がん患者の拡大により、カペシタビンのような治療オプションへのアクセスが増加することが必要であり、その結果、世界のがん患者の増加傾向に対抗するための重要な治療選択肢として市場の成長を牽引しています。

治療費の増加

薬代を含む医療費の増加に伴い、患者やヘルスケア・システムにとって経済的余裕が懸念事項となっています。様々ながんの治療に用いられる化学療法薬であるカペシタビンは、その高価さゆえに利用しにくくなり、患者のアドヒアランスや医療予算の制約に影響を与える可能性があります。個人やヘルスケア提供者の経済的負担の増大は、この薬剤へのアクセスを制限し、その普及を妨げ、がん患者の治療選択肢に影響を与える可能性があります。

経口化学療法の受け入れ拡大

経口薬であるカペシタビンは、標準的な静注化学療法と比較して、患者さんにとって利便性、柔軟性、そして治療期間中のQOLが向上します。加えて、通院は最低限で済み、自宅での自己投与も可能であるため、ヘルスケアの提供が簡素化され、費用も抑えられます。さらに、がん治療における経口化学療法への変化は、進化的な変化を示しています。経口製剤であるカペシタビンは、この動向をリードしており、より便利で利用しやすい治療選択肢を求める患者の需要を満たすことで、市場での地位を確立しています。これによって、市場の成長が促進されるであろう。

熟練した専門家の不足

カペシタビンのような薬剤を含む化学療法の実施には、専門的な知識と訓練が必要です。化学療法を管理・監督できる熟練した腫瘍内科医、看護師、薬剤師が不足していることは、カペシタビンの効果的な使用や処方を妨げる可能性があります。このような熟練した専門家の不足は、最適でない治療をもたらし、患者の転帰を損ない、薬剤の利用を制限する可能性があります。

COVID-19の影響

COVID-19の大流行は経済全体に顕著な影響を与えました。パンデミックにより多くの原薬製造工場が閉鎖され、原薬ビジネスは多くの困難に直面しました。その中には、サプライチェーンの混乱、原材料や包装資材の調達問題、労働力不足による操業能力の低下などがあった。しかし、COVID-19の状況が悪化すると、いくつかの医薬品の市場が急増し、生産関連原薬のニーズが高まった。

予測期間中、乳がんセグメントが最大となる見込み

乳がんセグメントが最大のシェアを占めると推定されます。経口化学療法薬であるカペシタビンは、転移性乳がんや手術後の補助療法など、さまざまなステージや種類の乳がんに広く利用されています。がん細胞の増殖を抑制する有効性と経口投与の利便性から、乳がん治療レジメンに好んで選択されています。併用療法または単独療法の一環として、乳がん細胞を標的とするカペシタビンの有効性はその意義を確立しており、乳がんと闘う患者の治療ニーズに対応する極めて重要な要素としての地位を固めています。

予測期間中にCAGRが最も高くなると予想されるのはカプセル剤セグメントです。

カプセル剤セグメントは、予測期間中に有利な成長が見込まれます。カペシタビンは一般的にカプセル剤で入手可能であり、化学療法を受ける患者に便利な経口投与経路を提供します。カプセルには活性薬剤が含まれているため、正確な投与が可能であり、摂取も容易です。さらに、カペシタビンのカプセル形態は、医療従事者と患者の双方に、様々な種類のがんを管理するための便利で効率的な選択肢を提供し、医薬品業界におけるその役割をさらに確固たるものにすることで、市場での存在感に大きく貢献しています。

最大のシェアを占める地域

アジア太平洋地域は、がんの蔓延と脆弱な老年人口により、予測期間中最大の市場シェアを占めました。さらに、特に中国、インド、日本などの人口基盤が大きいため、患者数が多く、市場の拡大を促進しています。さらに、製薬企業間の提携、がん医療を強化するための政府の取り組み、費用対効果の高いジェネリック医薬品の導入などが、アジア太平洋地域におけるカペシタビンの入手しやすさと普及をさらに後押ししています。

CAGRが最も高い地域：

北米には主要なジェネリック製薬企業が存在し、政府の取り組みや特別なコミュニティが増加していることから、予測期間中に利益率の高い成長が見込まれます。さらに、同地域の強固な医療インフラ、高度な研究施設、高いがん罹患率は、乳がんや大腸がんなど様々ながん種の治療におけるカペシタビンの大幅な活用に寄与しています。好意的な償還政策とヘルスケアへの投資の増加がカペシタビンの利用しやすさを支えており、北米はカペシタビンの利用と市場拡大の状況を形成する上で極めて重要な地域となっています。

無料のカスタマイズサービス

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のカペシタビン市場：医薬品タイプ別

• ジェネリック
• ブランド

第6章 世界のカペシタビン市場：適応症別

• 乳がん
• 結腸直腸がん
• その他の適応症

第7章 世界のカペシタビン市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界のカペシタビン市場：剤形別

• カプセル
• タブレット

第9章 カペシタビンの世界市場：エンドユーザー別

• 病院
• 専門センター
• ホームケア
• その他のエンドユーザー

第10章 世界のカペシタビン市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第11章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第12章 企業プロファイル

• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sanofi
• GSK plc
• Pfizer Inc.
• Novartis AG
• Lilly
• Bayer AG
• Merck & Co., Inc.
• Aurobindo Pharma
• Sun Pharmaceutical Industries Ltd.
• Alkem Labs Ltd
• Lupin
• Armas Pharmaceuticals, Inc
• Dr. Reddy's Laboratories Ltd.
• Cipla Inc.
• Fresenius SE & Co. KGaA
• Hikma Pharmaceuticals PLC
• Intas Pharmaceuticals Limited

List of Tables

• Table 1 Global Capecitabine Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 3 Global Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
• Table 4 Global Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
• Table 5 Global Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
• Table 6 Global Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 7 Global Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 8 Global Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 9 Global Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 10 Global Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 11 Global Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 12 Global Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 13 Global Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
• Table 14 Global Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
• Table 15 Global Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
• Table 16 Global Capecitabine Market Outlook, By End User (2021-2030) ($MN)
• Table 17 Global Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 18 Global Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
• Table 19 Global Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
• Table 20 Global Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 21 North America Capecitabine Market Outlook, By Country (2021-2030) ($MN)
• Table 22 North America Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 23 North America Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
• Table 24 North America Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
• Table 25 North America Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
• Table 26 North America Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 27 North America Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 28 North America Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 29 North America Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 30 North America Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 31 North America Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 32 North America Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 33 North America Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
• Table 34 North America Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
• Table 35 North America Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
• Table 36 North America Capecitabine Market Outlook, By End User (2021-2030) ($MN)
• Table 37 North America Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 38 North America Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
• Table 39 North America Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
• Table 40 North America Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 41 Europe Capecitabine Market Outlook, By Country (2021-2030) ($MN)
• Table 42 Europe Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 43 Europe Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
• Table 44 Europe Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
• Table 45 Europe Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
• Table 46 Europe Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 47 Europe Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 48 Europe Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 49 Europe Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 50 Europe Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 51 Europe Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 52 Europe Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 53 Europe Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
• Table 54 Europe Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
• Table 55 Europe Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
• Table 56 Europe Capecitabine Market Outlook, By End User (2021-2030) ($MN)
• Table 57 Europe Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 58 Europe Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
• Table 59 Europe Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
• Table 60 Europe Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 61 Asia Pacific Capecitabine Market Outlook, By Country (2021-2030) ($MN)
• Table 62 Asia Pacific Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 63 Asia Pacific Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
• Table 64 Asia Pacific Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
• Table 65 Asia Pacific Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
• Table 66 Asia Pacific Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 67 Asia Pacific Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 68 Asia Pacific Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 69 Asia Pacific Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 70 Asia Pacific Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 71 Asia Pacific Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 72 Asia Pacific Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 73 Asia Pacific Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
• Table 74 Asia Pacific Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
• Table 75 Asia Pacific Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
• Table 76 Asia Pacific Capecitabine Market Outlook, By End User (2021-2030) ($MN)
• Table 77 Asia Pacific Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 78 Asia Pacific Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
• Table 79 Asia Pacific Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
• Table 80 Asia Pacific Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 81 South America Capecitabine Market Outlook, By Country (2021-2030) ($MN)
• Table 82 South America Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 83 South America Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
• Table 84 South America Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
• Table 85 South America Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
• Table 86 South America Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 87 South America Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 88 South America Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 89 South America Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 90 South America Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 91 South America Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 92 South America Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 93 South America Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
• Table 94 South America Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
• Table 95 South America Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
• Table 96 South America Capecitabine Market Outlook, By End User (2021-2030) ($MN)
• Table 97 South America Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 98 South America Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
• Table 99 South America Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
• Table 100 South America Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 101 Middle East & Africa Capecitabine Market Outlook, By Country (2021-2030) ($MN)
• Table 102 Middle East & Africa Capecitabine Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 103 Middle East & Africa Capecitabine Market Outlook, By Generic (2021-2030) ($MN)
• Table 104 Middle East & Africa Capecitabine Market Outlook, By Branded (2021-2030) ($MN)
• Table 105 Middle East & Africa Capecitabine Market Outlook, By Indication (2021-2030) ($MN)
• Table 106 Middle East & Africa Capecitabine Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 107 Middle East & Africa Capecitabine Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 108 Middle East & Africa Capecitabine Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 109 Middle East & Africa Capecitabine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 110 Middle East & Africa Capecitabine Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 111 Middle East & Africa Capecitabine Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 112 Middle East & Africa Capecitabine Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 113 Middle East & Africa Capecitabine Market Outlook, By Drug Formulation (2021-2030) ($MN)
• Table 114 Middle East & Africa Capecitabine Market Outlook, By Capsules (2021-2030) ($MN)
• Table 115 Middle East & Africa Capecitabine Market Outlook, By Tablets (2021-2030) ($MN)
• Table 116 Middle East & Africa Capecitabine Market Outlook, By End User (2021-2030) ($MN)
• Table 117 Middle East & Africa Capecitabine Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 118 Middle East & Africa Capecitabine Market Outlook, By Speciality Centres (2021-2030) ($MN)
• Table 119 Middle East & Africa Capecitabine Market Outlook, By Homecare (2021-2030) ($MN)
• Table 120 Middle East & Africa Capecitabine Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Capecitabine Market is accounted for $ 436.36 million in 2023 and is expected to reach $ 696.13 million by 2030 growing at a CAGR of 6.9% during the forecast period. A chemotherapy drug called capecitabine is used to treat a variety of cancers, such as abdomen, colorectal, and breast cancers. It is commercialized under the trade name of XelodaCapecitabine is used as a monotherapy or metastatic treatment for breast cancer, while in cases of colorectal cancer, the drug is mostly used as neoadjuvant therapy with radiation. It is known for its efficacy, relatively manageable side effects, and its role in improving survival rates and quality of life for individuals battling various forms of cancer.

According to the American Cancer Society report, in 2017 about 135,430 new cases and 50,260 deaths were estimated due to colon and rectum cancer in the U.S.

Market Dynamics:

Driver:

Rising in cancer cases

Capecitabine, a chemotherapy medication, is widely used in the treatment of multiple cancer types, including breast, colorectal, and gastric cancers. Its oral administration, coupled with its ability to convert into an active form within the body, makes it a convenient and potent option for cancer therapy. The expanding pool of cancer patients necessitates increased access to treatment options like Capecitabine, thereby driving its market growth as a crucial therapeutic choice in combating the rising tide of cancer cases worldwide.

Restraint:

Increasing treatment costs

As healthcare expenses rise, including medication costs, affordability becomes a concern for patients and healthcare systems. Capecitabine, a chemotherapy drug used to treat various cancers, might become less accessible due to its higher cost, impacting patient adherence and healthcare budget constraints. The increasing financial burden on individuals and healthcare providers limits access to this medication, potentially hindering its widespread use and affecting treatment options for cancer patients.

Opportunity:

Growing acceptance of oral chemotherapy

As an oral medication, capecitabine offers patients more convenience, flexibility, and a better quality of life throughout treatment than standard intravenous chemotherapy. In addition, minimal hospital visits are required, and self-administration at home is an option, which simplifies healthcare delivery and lowers expenses. Moreover, the change in cancer treatment towards oral chemotherapy is indicative of an evolutionary change. Capecitabine, with its oral formulation, is leading this trend and has positioned itself well in the market by satisfying patient demand for more convenient and accessible treatment alternatives. Thereby, it will enhance market growth.

Threat:

Lack of Skilled Professionals

Administering chemotherapy, including drugs like Capecitabine, requires specialised knowledge and training. The shortage of proficient oncologists, nurses, and pharmacists capable of managing and overseeing chemotherapy procedures could impede the effective use and prescription of Capecitabine. This dearth of skilled professionals might result in suboptimal treatment, compromising patient outcomes, and potentially limiting the drug's utilization.

COVID-19 Impact

The COVID-19 pandemic had a notable effect on the overall economy. The pandemic caused many API manufacturing plants to close during this time, which presented the API business with a number of difficulties. Some of these were supply chain disruptions, issues in locating raw materials and packaging materials, and decreased operational capacity as a result of labour shortages. But when the COVID-19 situation worsened, there was a surge in the market for several medications, which raised the need for production-related APIs.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is estimated to hold the largest share. Capecitabine, an oral chemotherapy drug, is widely utilized in various stages and types of breast cancer, including metastatic breast cancer and adjuvant therapy after surgery. Its effectiveness in inhibiting cancer cell growth and its oral administration convenience make it a preferred choice in breast cancer treatment regimens. As part of combination therapies or standalone treatment, Capecitabine's efficacy in targeting breast cancer cells has established its significance, cementing its position as a pivotal component in addressing the therapeutic needs of patients battling breast cancer.

The capsules segment is expected to have the highest CAGR during the forecast period

The capsules segment is anticipated to have lucrative growth during the forecast period. Capecitabine is commonly available in capsule form, offering a convenient oral administration route for patients undergoing chemotherapy. The capsules contain the active drug, facilitating precise dosing and ease of intake. Moreover, the capsule form of Capecitabine contributes substantially to its market presence, providing both medical professionals and patients with a convenient and efficient option for managing various cancer types, further solidifying its role in the pharmaceutical landscape.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the prevalence of cancer and vulnerable geriatric population. Additionally, the region's large population base, particularly in countries like China, India, and Japan, offers a substantial patient pool, fostering market expansion. Moreover, collaborations between pharmaceutical companies, government initiatives to enhance cancer care, and the introduction of cost-effective generic versions further propel the accessibility and adoption of Capecitabine across the Asia-Pacific region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to the presence of key generic pharmaceutical companies in this region and the rise in government initiatives and special communities. Moreover, the region's robust healthcare infrastructure, advanced research facilities, and high prevalence of cancer contribute to the substantial utilisation of Capecitabine in the treatment of various cancer types, including breast and colorectal cancers. Favourable reimbursement policies and increasing investments in healthcare support the accessibility of Capecitabine, making North America a pivotal region in shaping the landscape of Capecitabine utilisation and market expansion.

Key players in the market:

Some of the key players in the Capecitabine Market include F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi, GSK plc, Pfizer Inc., Novartis AG, Lilly, Bayer AG, Merck & Co., Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Alkem Labs Ltd, Lupin, Armas Pharmaceuticals, Inc, Dr. Reddy's Laboratories Ltd., Cipla Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC and Intas Pharmaceuticals Limited.

Key Developments:

In December 2022, Shilpa Medicare announced that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer. This product launch may help the company to enhance their product portfolio and enhance business revenue.

In February 2021, Dr Reddy's Laboratories announced the launch of Capecitabine Tablets, USP, in the U.S. market. The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA). This product launch helped the company to enhance their product portfolio and enhance their business revenue.

Drug Types Covered:

• Generic
• Branded

Indications Covered:

• Breast Cancer
• Colorectal Cancer
• Other Indications

Distribution Channels Covered:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Drug Formulations Covered:

• Capsules
• Tablets

End Users Covered:

• Hospitals
• Speciality Centres
• Homecare
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Capecitabine Market, By Drug Type

• 5.1 Introduction
• 5.2 Generic
• 5.3 Branded

6 Global Capecitabine Market, By Indication

• 6.1 Introduction
• 6.2 Breast Cancer
• 6.3 Colorectal Cancer
• 6.4 Other Indications

7 Global Capecitabine Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacy
• 7.3 Retail Pharmacy
• 7.4 Online Pharmacy

8 Global Capecitabine Market, By Drug Formulation

• 8.1 Introduction
• 8.2 Capsules
• 8.3 Tablets

9 Global Capecitabine Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Speciality Centres
• 9.4 Homecare
• 9.5 Other End Users

10 Global Capecitabine Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 F. Hoffmann-La Roche Ltd.
• 12.2 Teva Pharmaceutical Industries Ltd.
• 12.3 Mylan N.V.
• 12.4 Sanofi
• 12.5 GSK plc
• 12.6 Pfizer Inc.
• 12.7 Novartis AG
• 12.8 Lilly
• 12.9 Bayer AG
• 12.10 Merck & Co., Inc.
• 12.11 Aurobindo Pharma
• 12.12 Sun Pharmaceutical Industries Ltd.
• 12.13 Alkem Labs Ltd
• 12.14 Lupin
• 12.15 Armas Pharmaceuticals, Inc
• 12.16 Dr. Reddy's Laboratories Ltd.
• 12.17 Cipla Inc.
• 12.18 Fresenius SE & Co. KGaA
• 12.19 Hikma Pharmaceuticals PLC
• 12.20 Intas Pharmaceuticals Limited